Zellera

Zellera is a biotechnology company focused on developing next-generation, off-the-shelf cell therapies for the treatment of cancer. The company leverages an induced pluripotent stem cell (iPSC) platform to engineer natural killer (NK) cells with enhanced potency and persistence. By utilizing a standardized manufacturing process, Zellera aims to overcome the limitations of patient-specific CAR-T therapies, providing scalable and cost-effective treatments for both solid tumors and hematologic malignancies. Their approach integrates advanced genetic engineering to optimize the immune response against difficult-to-treat cancers.